Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

CEO Of Black AIDS Institute Discusses HIV/AIDS At Newspaper Conference; Group Releases Report Examining HIV Testing In Black Community
Phill Wilson, CEO of the Black AIDS Institute (BAI), last week addressed the annual convention of the National Newspapers Publishers Association where he discussed the reasons blacks "were so slow to grasp the severity of the threat" of HIV, the NNPA/Seattle Medium reports. According to Wilson, many blacks believed that HIV/AIDS was not directly affecting their communities in the early years of the epidemic. In addition, he said when AIDS reached its peak between 1980 and 1982, blacks also were dealing with unemployment, poverty and welfare reform and, as a result, addressing HIV/AIDS was not a priority. Wilson also noted the reluctance by blacks to deal with the stigma related to the virus. Wilson said, however, "I"m more optimistic now around mobilizing black folks around HIV than [ever] before. I think we"ve made tremendous stride[s] and our institutions across the board are at a different place than they were" (Curry, 7/1).
generic viagra online
Prostate Cancer Patients Disease Free After Five Years Likely To Be Disease Free After 10 Years
Prostate cancer patients who receive brachytherapy and remain free of disease for five years or greater are unlikely to have a recurrence at 10 years, according to a study in the July 1 issue of the International Journal of Radiation Oncology Biology Physics, the official journal of the American Society for Radiation Oncology (ASTRO).
News of the day
Japanese Ministry Of Health Approves Rasilez(R), A First-in-class Direct Renin Inhibitor (DRI), For The Treatment Of High Blood Pressure
Rasilez® (aliskiren), the first new type of high blood pressure medicine in more than a decade, has been approved for use in Japan. Rasilez directly inhibits renin9, an enzyme that triggers a process leading to high blood pressure and organ damage. The Ministry of Health, Labour and Welfare (MHLW) in Japan approved Rasilez for the treatment of high blood pressure alone or in combination with other high blood pressure medicines.
Nutrition

Inflammatory Molecules Promote Liver Scarring

Scarring of the liver, which can progress to cirrhosis and/or cancer of the liver, is caused by persistent liver damage, such as occurs in those with untreated hepatitis C or alcoholism. Although such scarring (fibrosis) develops in an inflammatory environment, the role of inflammatory molecules has not been well defined. However, a team of researchers at Columbia University, New York, and UCSD, La Jolla, has established that the proteins CCR1 and CCR5 and the soluble inflammatory molecules that bind to them promote the development of liver fibrosis in mice. The team, led by Robert Schwabe and Ekihiro Seki, observed that expression of the inflammatory molecules MIP-1-alpha, MIP-1-beta, and RANTES, and the proteins to which they bind (CCR1 and CCR5), was increased in 2 mouse models of liver fibrosis. Consistent with a role for these molecules in the development of liver fibrosis, preventing the inflammatory molecules binding CCR1 and CCR5 reduced liver fibrosis, as did eliminating expression of either CCR1 or CCR5. The latter experiments also identified the cells on which CCR1 and CCR5 expression is important for promoting liver fibrosis. As expression of RANTES, CCR1, and CCR5 was detected in the livers of patients with cirrhosis, the authors suggest that targeting CCR1 and CCR5 (for which there are already small molecule inhibitors in clinical development) might be a viable approach to prevent liver fibrosis. TITLE: CCR1 and CCR5 promote hepatic fibrosis in mice AUTHORS: Robert F. Schwabe Columbia University, New York, New York, USA. Ekihiro Seki University of California, San Diego, La Jolla, California, USA. View the PDF of this article at: https://www.the-jci.org/article.php?id=37444 Karen Honey Journal of Clinical Investigation JCI online early table of contents: June 15, 2009


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009